You don’t have to wear a cape to be a hero! Meet some of our researchers, kids, donors and fundraisers.


Tegan was diagnosed with Acute Lymphoblastic Leukemia (ALL) on August 13, 2011. She was just two-and-a-half years old. Instead of learning about seasons, colours, and how to print her name, Tegan spent her pre-school year learning about pokes, blood-clots, and chemo. On October 24, 2013, Tegan took her last chemo pill. Today, she is an active seven year old who loves to colour and play with her big sister, Jessie. Tegan’s parents are grateful for the support of Canadians who open their hearts and wallets to fund research that finds more cures and better treatments for kids like their daughter.

MeetOurHeroes_SideArrow@2x copy

Childhood Cancer Hero


Childhood Cancer Hero



Jadyn was diagnosed with a brain tumour called Anaplastic Ependymoma at age five, and has relapsed seven times. She’s had cancer for most of her life. Enduring multiple surgeries and rounds of chemotherapy, Jadyn is Canada’s most radiated child. Despite this, her joy for life is contagious— she loves telling jokes and riddles, and would love to introduce you to her dog named Cure. Strong, feisty and funny, Jadyn is passionate about sharing her childhood cancer journey with others by speaking at fundraising events whenever she can.


Tobin was just two years old when he was first diagnosed with a brain tumour, Anaplastic Ependymoma. He underwent surgery to remove the tumour, followed by radiation and chemotherapy. Throughout his cancer journey, Tobin received incredible support from his family — especially his amazing sister, Katriel. Despite relapses, surgeries, and complications, Tobin has grown to be a talented athlete, actor and student. Today, Tobin is looking forward to graduating from high school and hopes to receive a Childhood Cancer Canada Survivor Scholarship to study nursing.

MeetOurHeroes_SideArrow@2x copy

Childhood Cancer Hero


Childhood Cancer Hero



Helena was diagnosed with Acute Lymphoblastic Leukemia (ALL) at age three after her parents took her to the doctor for a persistent ear ache. She underwent 841 days of chemotherapy— more than two years of pokes, pills and hospital stays. Today, Helena has passed the five-year anniversary of being diagnosed with cancer and is a happy and vibrant ten year old who loves karate, fishing, theatre, and going to camp. She is grateful for every dollar raised for childhood cancer research, and shares her story whenever she can to help kids just like her!


Diana was diagnosed with Hodgkin’s Lymphoma at age 12 and again at age 15. While pursuing a PhD in Cancer Genomics at the Hospital for Sick Children, she was diagnosed with a sarcoma on her back. Diana is a Teva Canada Scholarship recipient and today she is a Postdoctoral Fellow in the Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda Maryland. Her research focuses on the genetic determinants of risk to second cancers in childhood cancer survivors. She studies cancer survivors’ genomic makeup and how it may be related to an increased predisposition to second cancers, and what can be done do to reduce these risks.

MeetOurHeroes_SideArrow@2x copy

Teva Scholarship Recipient


McMaster Children’s Hospital



Dr. Klassen’s research focuses on adolescents and young adults with cancer, patients who face challenges because of their developmental stage and social situation. Dr. Klassen and her colleague, Dr. Norma D’agostino, are working on modifying a distress screening tool for adolescents and young adults with cancer who face unique challenges in their cancer journey so that health care professionals can recognize distress in these patients and address it promptly. Dr. Klassen’s research is made possible by generous donors like you.


When a child with a solid tumour relapses, their challenges often include decreased appetite and weight loss. Studies have shown that melatonin, widely used for the therapy of sleep disturbances, may also be helpful in treating decreased appetite and weight loss in adults who have relapsed cancer. The goal of Dr. Johnston’s study is to find a pediatric dose for melatonin that is comparable to the high adult dose, and is tolerated in children. Your generous support makes Dr. Johnston’s research possible.

MeetOurHeroes_SideArrow@2x copy

Children’s Hospital of Eastern Ontario


BC Children’s Hospital



Dr. Schultz and his CIHR Late Effects team are assessing biomarkers to identify children who are at risk of adverse effects of their successful cancer treatments. Identifying these high-risk children will lead to preemptive and timely therapies that could potentially cure children of their cancers, without effects of treatment like hearing loss, kidney failure, and chronic graft-versus host disease.